Manjie Xing

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10545861/publications.pdf Version: 2024-02-01



MANUE XINC

#	Article	IF	CITATIONS
1	Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. Gut, 2023, 72, 226-241.	12.1	6
2	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Gut, 2022, 71, 1277-1288.	12.1	23
3	Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. Cancer Research, 2022, 82, 2538-2551.	0.9	7
4	Highly recurrent CBS epimutations in gastric cancer CpG island methylator phenotypes and inflammation. Genome Biology, 2021, 22, 167.	8.8	10
5	Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer. Genome Medicine, 2021, 13, 158.	8.2	7
6	<i>HNF4α</i> pathway mapping identifies wild-type <i>IDH1</i> as a targetable metabolic node in gastric cancer. Gut, 2020, 69, 231-242.	12.1	27
7	Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent <i>CCNE1</i> and <i>IGF2</i> enhancer hijacking in primary gastric adenocarcinoma. Gut, 2020, 69, 1039-1052.	12.1	36
8	Cross-species chromatin interactions drive transcriptional rewiring in Epstein–Barr virus–positive gastric adenocarcinoma. Nature Genetics, 2020, 52, 919-930.	21.4	65
9	Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. Journal of Clinical Investigation, 2020, 130, 3005-3020.	8.2	12
10	Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers. Nature Communications, 2018, 9, 1520.	12.8	109
11	Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. Cancer Cell, 2018, 33, 137-150.e5.	16.8	175
12	HoxC5 and miR-615-3p target newly evolved genomic regions to repress hTERT and inhibit tumorigenesis. Nature Communications, 2018, 9, 100.	12.8	38
13	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discovery, 2017, 7, 630-651.	9.4	48
14	<i>VHL</i> Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. Cancer Discovery, 2017, 7, 1284-1305.	9.4	111
15	Epigenomic Consequences of Coding and Noncoding Driver Mutations. Trends in Cancer, 2016, 2, 585-605.	7.4	8
16	Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. Nature Communications, 2016, 7, 12983.	12.8	123
17	Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements. Nature Communications, 2014, 5, 4361.	12.8	72